Calvert Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Calvert Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,617	Closed	-$313K	–	800
2016 Q3	$313K	Buy	4,617 +304	+7%	+$21.4K	0.01%	642
2016 Q2	$239K	Buy	4,313 +36	+0.8%	+$2.27K	0.01%	684
2016 Q1	$268K	Buy	4,277 +698	+20%	+$46.4K	0.01%	633
2015 Q4	$337K	Buy	3,579 +612	+21%	+$56.7K	0.02%	537
2015 Q3	$238K	Buy	2,967 +119	+4%	+$13.2K	0.01%	534
2015 Q2	$341K	Sell	2,848 -294	-9%	-$35.1K	0.02%	464
2015 Q1	$328K	Buy	3,142 +692	+28%	+$70.1K	0.02%	476
2014 Q4	$238K	Buy	+2,450	New	+$227K	0.02%	519

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Calvert Investment Management's ALNY Position: Q4 2016 in Review

Calvert Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 4,617 shares — an estimated $313K sold.

Calvert Investment Management first reported a position in ALNY in Q4 2014 and held it in 8 quarters. The position peaked at $341K in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Calvert Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Calvert Investment Management sold 4,617 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $313K.
Calvert Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Calvert Investment Management's Alnylam Pharmaceuticals position peaked at $341K in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Calvert Investment Management's 13F filing for Q4 2016, filed 13 Feb 2017.